ZA202001167B - Glucagon-like peptide 1 receptor agonists and uses thereof - Google Patents
Glucagon-like peptide 1 receptor agonists and uses thereofInfo
- Publication number
- ZA202001167B ZA202001167B ZA2020/01167A ZA202001167A ZA202001167B ZA 202001167 B ZA202001167 B ZA 202001167B ZA 2020/01167 A ZA2020/01167 A ZA 2020/01167A ZA 202001167 A ZA202001167 A ZA 202001167A ZA 202001167 B ZA202001167 B ZA 202001167B
- Authority
- ZA
- South Africa
- Prior art keywords
- glp1
- peptide
- glucagon
- modified
- receptor agonists
- Prior art date
Links
- 239000003877 glucagon like peptide 1 receptor agonist Substances 0.000 title 1
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 abstract 3
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 108020001507 fusion proteins Proteins 0.000 abstract 3
- 229920001184 polypeptide Polymers 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 229940089838 Glucagon-like peptide 1 receptor agonist Drugs 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- GCYXWQUSHADNBF-AAEALURTSA-N preproglucagon 78-108 Chemical class C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 GCYXWQUSHADNBF-AAEALURTSA-N 0.000 abstract 1
- 230000000087 stabilizing effect Effects 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
- C07K16/081—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from DNA viruses
- C07K16/082—Hepadnaviridae, e.g. hepatitis B virus
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/62—DNA sequences coding for fusion proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Wood Science & Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Child & Adolescent Psychology (AREA)
- Neurology (AREA)
- Toxicology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Microbiology (AREA)
- Virology (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762562283P | 2017-09-22 | 2017-09-22 | |
| PCT/US2018/052110 WO2019060653A1 (en) | 2017-09-22 | 2018-09-21 | GLP-1 RECEPTOR AGONISTS (GLUCAGON-LIKE PEPTIDE 1) AND USES THEREOF |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA202001167B true ZA202001167B (en) | 2024-06-26 |
Family
ID=63799082
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA2020/01167A ZA202001167B (en) | 2017-09-22 | 2020-02-25 | Glucagon-like peptide 1 receptor agonists and uses thereof |
Country Status (14)
| Country | Link |
|---|---|
| US (4) | US11045522B2 (enExample) |
| EP (1) | EP3684793A1 (enExample) |
| JP (3) | JP7239566B2 (enExample) |
| KR (1) | KR102696518B1 (enExample) |
| CN (2) | CN118955732A (enExample) |
| AU (2) | AU2018338178B2 (enExample) |
| CA (1) | CA3073964A1 (enExample) |
| EA (1) | EA202090649A1 (enExample) |
| IL (2) | IL273253B2 (enExample) |
| MX (1) | MX2020002977A (enExample) |
| MY (2) | MY207828A (enExample) |
| SG (1) | SG11202001637PA (enExample) |
| WO (1) | WO2019060653A1 (enExample) |
| ZA (1) | ZA202001167B (enExample) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MY207828A (en) * | 2017-09-22 | 2025-03-21 | Regeneron Pharma | Glucagon-like peptide 1 receptor agonists and uses thereof |
| US12122817B2 (en) * | 2020-09-22 | 2024-10-22 | Serpentide Inc. | Long-lasting GLP1 analogue drug for type-2 diabetes |
| CN116670171A (zh) * | 2020-12-03 | 2023-08-29 | 免疫新炉有限公司 | 包括glp-1受体激动剂和抗oscar抗体的融合蛋白及其用途 |
| WO2022117044A1 (en) * | 2020-12-03 | 2022-06-09 | Sunshine Lake Pharma Co., Ltd. | Glp-1/gcg dual receptor agonist polypeptide and fusion protein thereof |
| CN112716966B (zh) * | 2021-02-03 | 2022-05-03 | 浙江诺得药业有限公司 | 一种恩格列净药用组合物及其制备方法 |
| CN113461785B (zh) * | 2021-04-13 | 2022-10-14 | 湖南中晟全肽生化有限公司 | Glp-1受体激动剂及其应用 |
| CN119638849A (zh) * | 2021-10-18 | 2025-03-18 | 深圳科兴药业有限公司 | 一种生长激素融合蛋白及其应用 |
| CN114788876B (zh) * | 2022-02-24 | 2024-07-05 | 北京医院 | 治疗糖尿病的mRNA药物制剂及其制备方法与应用 |
| US20250289861A1 (en) * | 2022-05-04 | 2025-09-18 | Immunoforge Co.,Ltd. | Fusion protein comprising glp-1, immunoglobulin fc, and igf-1 and use thereof |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
| CN117143242B (zh) * | 2023-10-30 | 2024-03-29 | 南京佰抗生物科技有限公司 | 抗Galectin-3蛋白的单克隆抗体组合物及应用 |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| US20250270274A1 (en) * | 2024-02-26 | 2025-08-28 | Serpentide Inc. | Super long-lasting glp1 or glp1/gip analogue drug for type-2 diabetes and obesity |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2004251145C1 (en) | 2003-06-12 | 2011-04-14 | Eli Lilly And Company | GLP-1 analog fusion proteins |
| US8257740B1 (en) | 2011-08-15 | 2012-09-04 | Gp Medical, Inc. | Pharmaceutical composition of nanoparticles |
| US20060275288A1 (en) | 2005-01-20 | 2006-12-07 | Grihalde Nelson D | GLP-1 receptor agonist and allosteric modulator monoclonal antibodies and uses thereof |
| US8246995B2 (en) | 2005-05-10 | 2012-08-21 | The Board Of Trustees Of The Leland Stanford Junior University | Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells |
| US8497240B2 (en) | 2006-08-17 | 2013-07-30 | Amylin Pharmaceuticals, Llc | DPP-IV resistant GIP hybrid polypeptides with selectable properties |
| AR064623A1 (es) | 2006-12-21 | 2009-04-15 | Centocor Inc | Uso de agonistas del receptor de glp -1 de accion prolongada para mejorar la sensibilidad a la insulina y los perfiles lipidicos |
| WO2009020802A2 (en) | 2007-08-03 | 2009-02-12 | Eli Lilly And Company | Treatment for obesity |
| EP2190872B1 (en) | 2007-09-05 | 2018-03-14 | Novo Nordisk A/S | Glucagon-like peptide-1 derivatives and their pharmaceutical use |
| LT2373681T (lt) | 2008-12-10 | 2017-04-10 | Glaxosmithkline Llc | Albiglutido farmacinės kompozicijos |
| US20120148586A1 (en) | 2009-08-27 | 2012-06-14 | Joyce Ching Tsu Chou | Glucagon-like protein-1 receptor (glp-1r) agonists for treating autoimmune disorders |
| WO2011043530A1 (ko) * | 2009-10-09 | 2011-04-14 | (주)알테오젠 | Ｇｌｐ-1 유사체의 융합체, 및 이를 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 조성물 |
| WO2011056644A2 (en) | 2009-10-28 | 2011-05-12 | Centocor Ortho Biotech Inc. | Anti-glp-1r antibodies and their uses |
| US20120294855A1 (en) | 2009-11-03 | 2012-11-22 | Eli Lilly & Company | Glp-1 receptor agonist compounds for obstructive sleep apnea |
| SG11201500682WA (en) | 2012-09-07 | 2015-02-27 | Sanofi Sa | Fusion proteins for treating a metabolic syndrome |
| ES2687083T3 (es) | 2013-01-17 | 2018-10-23 | Vtv Therapeutics Llc | Combinaciones de un agonista del GLPR1 y metformina y el uso de estos para el tratamiento de la diabetes tipo 2 y otros trastornos |
| US20150259416A1 (en) | 2014-03-12 | 2015-09-17 | Biocrine Ab | Methods for treating and/or limiting development of diabetes |
| CN104371019B (zh) | 2013-08-13 | 2019-09-10 | 鸿运华宁（杭州）生物医药有限公司 | 一种能与glp-1r特异性结合的抗体及其与glp-1的融合蛋白质 |
| CN104098702B (zh) | 2014-07-23 | 2017-06-16 | 湖北工业大学 | 一种利用mfh融合蛋白制备glp‑1多肽或其类似物方法和应用 |
| CN106390100B (zh) * | 2015-01-28 | 2021-06-22 | 中国科学院天津工业生物技术研究所 | 一种多肽复合物作为glp-1药物载体的应用、方法及其融合蛋白复合物 |
| PL3257524T3 (pl) | 2015-02-11 | 2021-03-08 | Gmax Biopharm Llc | Stabilny preparat farmaceutyczny w postaci roztworu białka fuzyjnego przeciwciała przeciwko glp-1r |
| TWI622596B (zh) | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| WO2017211922A2 (en) * | 2016-06-09 | 2017-12-14 | Medimmune Limited | Protease-resistant mono-lipidated peptides |
| MY207828A (en) * | 2017-09-22 | 2025-03-21 | Regeneron Pharma | Glucagon-like peptide 1 receptor agonists and uses thereof |
-
2018
- 2018-09-21 MY MYPI2023002759A patent/MY207828A/en unknown
- 2018-09-21 IL IL273253A patent/IL273253B2/en unknown
- 2018-09-21 SG SG11202001637PA patent/SG11202001637PA/en unknown
- 2018-09-21 CA CA3073964A patent/CA3073964A1/en active Pending
- 2018-09-21 WO PCT/US2018/052110 patent/WO2019060653A1/en not_active Ceased
- 2018-09-21 JP JP2020516667A patent/JP7239566B2/ja active Active
- 2018-09-21 CN CN202410964216.3A patent/CN118955732A/zh active Pending
- 2018-09-21 US US16/137,662 patent/US11045522B2/en active Active
- 2018-09-21 EA EA202090649A patent/EA202090649A1/ru unknown
- 2018-09-21 AU AU2018338178A patent/AU2018338178B2/en active Active
- 2018-09-21 IL IL304574A patent/IL304574B2/en unknown
- 2018-09-21 MY MYPI2020000984A patent/MY200364A/en unknown
- 2018-09-21 EP EP18783613.5A patent/EP3684793A1/en active Pending
- 2018-09-21 CN CN201880061327.6A patent/CN111108117B/zh active Active
- 2018-09-21 MX MX2020002977A patent/MX2020002977A/es unknown
- 2018-09-21 KR KR1020207011414A patent/KR102696518B1/ko active Active
-
2020
- 2020-02-25 ZA ZA2020/01167A patent/ZA202001167B/en unknown
-
2021
- 2021-05-27 US US17/332,215 patent/US11779633B2/en active Active
-
2023
- 2023-03-01 JP JP2023030635A patent/JP7559112B2/ja active Active
- 2023-08-29 US US18/457,482 patent/US12090193B2/en active Active
- 2023-09-04 AU AU2023223010A patent/AU2023223010B2/en active Active
-
2024
- 2024-08-14 US US18/804,421 patent/US20250000949A1/en active Pending
- 2024-09-17 JP JP2024159697A patent/JP7789871B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202001167B (en) | Glucagon-like peptide 1 receptor agonists and uses thereof | |
| PE20191551A1 (es) | Polipeptidos de union al receptor de transferrina disenados | |
| MX365551B (es) | Proteinas de fusion de apelina y usos de estas. | |
| BR112016016411A2 (pt) | VARIANTES DE REGIÕES-"Fc" COM PROPRIEDADES DE LIGAÇÃO DE "FcRn" MODIFICADAS | |
| MY183025A (en) | Fusion proteins | |
| CY1126121T1 (el) | Πρωτεϊνες συντηξης υποδοχεα tgf-bhta τυπου ii και χρησεις aυτων | |
| MX382848B (es) | Variantes de región fc con propiedades de unión a receptor fc neonatal (fcrn) modificadas y de unión a proteína a mantenidas. | |
| WO2016161244A3 (en) | Methods and compositions related to gpcr agonist polypeptides | |
| SG10201808523RA (en) | Il-22 polypeptides and il-22 fc fusion proteins and methods of use | |
| MX382908B (es) | Polipéptidos de folistatina y sus usos. | |
| EA201791238A1 (ru) | Способы и композиции, в которых используются варианты полипептидов klotho | |
| EA201590525A1 (ru) | Слитые белки для лечения метаболического синдрома | |
| EP3870211A4 (en) | GLUCAGON-LIKE PEPTIDE 1 (GLP1) GROWTH DIFFERENTIATION FACTOR 15 (GDF15) FUSION PROTEINS AND THEIR USES | |
| PE20081804A1 (es) | Polipeptidos del receptor de activina variante y usos de los mismos | |
| MX2021005725A (es) | Tratamiento de la obesidad y sus complicaciones. | |
| ES2722773T3 (es) | Polipéptidos de fHbp meningocócicos modificados | |
| EA202190240A1 (ru) | Варианты рекомбинантного белка | |
| BR112017017609A2 (pt) | proteína de fusão fc, e, composição farmacêutica. | |
| EP4491268A3 (en) | Fc binding proteins with cysteine in the c-terminal helical region | |
| WO2018129200A3 (en) | Pac1 receptor agonists (maxcaps) and uses thereof | |
| MX2019012506A (es) | Formulaciones estables de proteinas de dominio andamio a base de fibronectina que se unen a miostatina. | |
| MX2025010859A (es) | Polipéptidos de fusión dap10/dap12. | |
| PH12018501319A1 (en) | Insulinotropic peptide derivative with modified n-terminal charge | |
| PH12020551582A1 (en) | Lfa3 variants and compositions and uses thereof | |
| PH12017550079A1 (en) | Composition for improving memory, learning ability and cognition |